Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022
TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services...
TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services...
Loos, France, Isovital Headquarter, Oct 12th 2022 - Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDERClaude Poliart, founder and manager...
Novel name reflects expansion of capabilities and solutionsSAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY),...
TEL AVIV, Israel, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
Anticipates total third quarter net sales of $21.5-$22.5 million, up 10-15% compared to the prior year period Restructured balance sheet...
Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients...
LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of...
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid...
TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2022LEXINGTON, Mass., Oct. 12, 2022 (GLOBE...
Six abstracts selected for presentation, including three oral presentationsWALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc.,...
- Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation - - VRDN-001 10mg/kg proof of concept...
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today...
-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application...
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Accomplished industry leader with over twenty years of experience building lasting relationships with global regulatory agencies and guidance in the...
Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors show safe and...
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused...
Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administrationROCKVILLE, Md., Oct. 12, 2022...